Venus Concept Receives FDA 510(k) Clearance of Venus BlissMAX
Venus Concept Inc announces it has received 510(k) clearance from the US Food and Drug Administration to market the Venus BlissMAX device in the United States.
Venus Concept Inc announces it has received 510(k) clearance from the US Food and Drug Administration to market the Venus BlissMAX device in the United States.
A clinical trial involving 828 patients found that three weeks of radiation following mastectomy did not increase reconstruction complications compared with the standard five-week course.